Clinical Trial Update: A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A randomized Phase 2 neoadjuvant study comparing weekly paclitaxel with or without the SMAC mimetic LCL161 in triple-negative breast cancer has completed and po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• LCL161
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-08-31